// App-Quantinova.ai

93 : A phase Ib study of NUC-3373 in combination with standard therapies in advanced/metastatic colorectal cancer (NuTide:302).

Researchers

Presenter

  • Andrew L. Coveler

Principal Investigators

  • Farasat Kazmi

  • Kristen Keon Ciombor

  • Janet Graham

  • Lisa Jane Rodgers

  • Michelle Myers

  • Jordan Berlin

  • Sarah Patricia Blagden

  • T.R. Jeffry Evans

Medical Centers

  • Seattle Cancer Care Alliance/University of Washington, Seattle, WA

  • Early Phase Clinical Trials Unit, Oxford, United Kingdom

  • Vanderbilt University Medical Center, Nashville, TN

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • MRC, Edinburgh, United Kingdom

  • University of Oxford, Oxford, United Kingdom

  • University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

Biomarkers

  • Epidermal growth factor receptor

  • Vascular endothelial growth factor A

Drug/Treatment

  • Oxaliplatin

  • Irinotecan

  • NUC3373

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved